Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: impact of psychiatric co-morbidity
Cocaine is associated with serious health problems including psychiatric co‐morbidity. There is a need for the identification of biomarkers for the stratification of cocaine‐addicted subjects. Several studies have evaluated circulating endocannabinoid‐related lipids as biomarkers of inflammatory, me...
Saved in:
Published in | Addiction biology Vol. 18; no. 6; pp. 955 - 969 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.11.2013
John Wiley & Sons, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Cocaine is associated with serious health problems including psychiatric co‐morbidity. There is a need for the identification of biomarkers for the stratification of cocaine‐addicted subjects. Several studies have evaluated circulating endocannabinoid‐related lipids as biomarkers of inflammatory, metabolic and mental disorders. However, little is known in substance use disorders. This study characterizes both free N‐acyl‐ethanolamines (NAEs) and 2‐acyl‐glycerols in abstinent cocaine addicts from outpatient treatment programs who were diagnosed with cocaine use disorder (CUD; n = 88), and age‐/gender‐/body mass‐matched healthy control volunteers (n = 46). Substance and mental disorders that commonly occur with substance abuse were assessed by the semi‐structured interview ‘Psychiatric Research Interview for Substance and Mental Diseases' according to the ‘Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision’ (DSM‐IV‐TR) and plasma‐free acyl derivatives were quantified by a liquid chromatography‐tandem mass spectrometry system. The results indicate that plasma acyl derivatives are altered in abstinent cocaine‐addicted subjects with CUD (CUD subjects). While NAEs were found to be increased, 2‐acyl‐glycerols were decreased in CUD subjects compared with controls. Multivariate predictive models based on these lipids as explanatory variables were developed to distinguish CUD subjects from controls providing high discriminatory power. However, these alterations were not influenced by the DSM‐IV‐TR criteria for cocaine abuse and dependence as cocaine trait severity measure. In contrast, we observed that some free acyl derivatives in CUD subjects were found to be affected by the diagnosis of some co‐morbid psychiatric disorders. Thus, we found that the monounsaturated NAEs were significantly elevated in CUD subjects diagnosed with mood [N‐oleoyl‐ethanolamine and N‐palmitoleoyl‐ethanolamine (POEA)] and anxiety (POEA) disorders compared with non‐co‐morbid CUD subjects. Interestingly, the coexistence of alcohol use disorders did not influence the circulating levels of these free acyl derivatives. In summary, we have identified plasma‐free acyl derivatives that might serve as reliable biomarkers for CUD. Furthermore, we found that monounsaturated NAE levels are also enhanced by co‐morbid mood and anxiety disorders in cocaine addicts. These findings open the way for the development of new strategies for cocaine addiction diagnosis and treatment. |
---|---|
Bibliography: | istex:8A0688B5B390DBF5EF8C8D0F6709F5436F18D2E4 ArticleID:ADB12107 Consejería de Economía, Innovación y Ciencia, Junta de Andalucía UE-FEDER - No. CTS-433 Consejería de Salud, Junta de Andalucía - No. SAS 111224 Figure S1 Correlation analyses between plasma levels of NAEs and 2-acyl-glycerols, and DSM-IV criteria for cocaine abuse and dependence in CUD-subjects Figure S2 Plasma levels of NAEs and 2-acyl-glycerols in CUD-subjects with comorbid alcohol use disorders Table S1 Binary logistic regression models for distinguishing cocaine use disorders (CUD) with the plasma concentrations of NAEs and polyunsaturated 2-acyl-glycerols Instituto de Salud Carlos III, Red de Trastornos Adictivos UE-FEDER 2006 and 2012 - No. RD06/0001/0000; No. RD12/0028/0001; No. RD06/0001/1009; No. RD12/0028/0009 ark:/67375/WNG-CQJ3FP1Q-W Plan Nacional sobre Drogas - No. 049/2009 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1355-6215 1369-1600 1369-1600 |
DOI: | 10.1111/adb.12107 |